J&J diabetic foot gel undergoes FDA safety review

03/28/2008 | CNNMoney · Reuters

The FDA will conduct a safety review of Johnson & Johnson's Regranex after a study found a potential link between the diabetic foot gel and a higher risk of cancer-related deaths. A J&J spokeswoman said the company is working with the FDA and remains "confident in the safety and effectiveness" of the product.

View Full Article in:

CNNMoney · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN